EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Aadi Bioscience's Enterprise Value is €-40.14 Mil.
Aadi Bioscience's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2024 was €-56.68 Mil. Therefore, Aadi Bioscience's EV-to-FCF for today is 0.71.
The historical rank and industry rank for Aadi Bioscience's EV-to-FCF or its related term are showing as below:
FRA:3350'
s EV-to-FCF Range Over the Past 10 Years
Min: -16.22 Med: -1.66 Max: 161.81
Current: 0.71
During the past 4 years, the highest EV-to-FCF of Aadi Bioscience was 161.81. The lowest was -16.22. And the median was -1.66.
FRA:3350's EV-to-FCF is ranked better than 71.05% of 380
companies
in the Biotechnology industry
Industry Median: 8.375
vs FRA:3350: 0.71
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The historical data trend for Aadi Bioscience's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Aadi Bioscience's EV-to-FCF
For the Biotechnology subindustry, Aadi Bioscience's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aadi Bioscience's EV-to-FCF Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Aadi Bioscience's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Aadi Bioscience's EV-to-FCF falls into.
Aadi Bioscience's current Enterprise Value is €-40.14 Mil.
Aadi Bioscience's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-56.68 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aadi Bioscience (FRA:3350) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Aadi Bioscience's PE Ratio for today is calculated as:
Aadi Bioscience's share price for today is €1.58.
Aadi Bioscience's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-2.356.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Aadi Bioscience EV-to-FCF Related Terms
Thank you for viewing the detailed overview of Aadi Bioscience's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
Aadi Bioscience Inc is a clinical-stage biopharmaceutical company developing precision therapies for genetically-defined cancers. Aadi's primary goal is to bring transformational therapies to cancer patients with mTOR pathway driver alterations such as alterations in TSC1 or TSC2 genes, where other mTOR inhibitors have not or cannot be effectively exploited due to problems of pharmacology, effective drug delivery, safety, or effective targeting to the disease site. It has one operating segment, which is the business of developing and commercializing proprietary therapeutic. Geographically, it is located in the United States.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
FRA:3350 has been successfully added to your 